secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0000950170-22-021600
Event type: other_material
Sentiment:  positive
Materiality: 0.45
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio announces two abstracts accepted for ASH 2022 annual meeting
-------------------------------------------------------------------------

- Abstract #5965 describes beta-globin gene replacement strategy for beta-thalassemia using UltraHDR platform.
- Abstract #3468 (poster) details single-cell RNA sequencing method to assess gene-editing outcomes in sickle cell disease.
- CEO Josh Lehrer notes initial proof-of-concept data for nula-cel (SCD therapy) expected mid-2023.
- Nula-cel is a first-in-human gene correction therapy; FDA granted Fast Track and Orphan Drug designations.
- ASH meeting takes place Dec 10-13, 2022 in New Orleans.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000095017022021600/0000950170-22-021600-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000095017022021600/grph-20221103.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-021600

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer